Molika Ashford

The company is seeing its CYP2C19 test adopted broadly as it prepares to submit a new application to the FDA for an assay targeting neurodegenerative disease.

Researchers described the process they took to adapt their methodology for improved BRCA variant classification through ClinGen in a new study this week.

Guardant reached a major milestone in Q2 with the FDA approval of its Guardant Shield liquid biopsy colon cancer screening test.

The company increased its core customer base compared to the same period of 2023 and cited positive signs for its newest platform expansions.

The company said it screened more that 1 million people for colorectal cancer during the quarter, and also tested a record number with its Oncotype DX breast cancer test.

The company is gearing up to launch a new rapid NGS test for acute myeloid leukemia and a liquid biopsy comprehensive genomic profiling assay.

Neurologists treating patients who present with a small stroke or transient ischemic attack are now able to get PGx results to inform their prescription of Plavix within 24 hours.

Investigators from Atrium Health recently published a study comparing pretreatment and posttreatment testing, showing a strong benefit in a real-world clinical cohort.

The company closed its doors June 30, according to a Worker Adjustment and Retraining Notification filed in California.

Investigators developed a methylation-based framework for detecting and classifying cancers, which they hope can be adapted for screening and other applications.